$ADPT

LO FRANCIS sold $3.2M of ADPT

LO FRANCIS (Chief People Officer) sold 115,406 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.06 ($28.02–$28.57, $3.24M total) across 2 trades on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LO FRANCIS
Published Sep 19, 2026, 12:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
medium confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The sale reduces insider ownership, which may be interpreted as a slight negative signal, but the size is modest relative to market cap.

02

Market read

A routine insider sale with modest dollar amount; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or compensation plans not disclosed could influence the insider's decision.

Relevance 5/10Novelty 4/10Timing: post‑market filing 2026‑09‑18

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ADPTNeutralMedium confidence
Context

Chief People Officer sold 115,406 shares for $3.24M via a 10b5‑1 plan, reducing holdings to 220,867 shares.

Expected impact

Potential modest downside pressure of 1‑2% in the next trading session.

Evidence & confidence

A $3.2M sale by a senior officer is material but not large enough to trigger a sharp move; market may view it as routine.

Market effects

Minimal impact on the biotech sector; insider sales are common and unlikely to shift sector sentiment.

No regional effect; the filing is US‑specific.

Negligible on a global scale.

Counterpoint

The sale could be a portfolio rebalancing unrelated to company outlook, so price may remain stable.

Key entities

  • Adaptive Biotechnologies Corp

    Biotech firm listed on NASDAQ under ticker ADPT.

  • Lo Francis

    Chief People Officer of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene

$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.